Trial Search Results

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in patients receiving chemotherapy for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or high-risk myelodysplasia (MDS). In this study, the safety, tolerability and activity of CLT-008 administered after "standard of care" cytarabine-based consolidation or induction/re-induction chemotherapy will be determined by monitoring for adverse reactions, infusion reactions, graft-versus host disease (GVHD), neutrophil and platelet recovery, hMPC persistence, infections and complications.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Cellerant Therapeutics

Collaborator: Department of Health and Human Services

Stanford Investigator(s):

Intervention(s):

  • Biological: human myeloid progenitor cells
  • Drug: G-CSF

Phase:

Phase 1/Phase 2

Eligibility


Key Inclusion Criteria:

   - Hematological malignancy, including:

      - AML, ALL or MDS

   - Planned treatment with cytarabine-based chemotherapy regimen

   - Adequate hepatic, renal, hematologic, cardiac and respiratory function

Key Exclusion Criteria:

   - Prior allograft or history of active GVHD within 3 years

   - Pregnant or nursing

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting